Innovation in the pharmaceutical industry

Ansell J. Converging Targets: R&D Strategies of the Top 20 Pharmaceutical Companies. Thame: Decision Resources, October 1997

Östholm I. Drug Discovery: a Pharmacist's Story. Stockholm: Swedish Pharmaceutical Press, 1995

Lahana R. How many leads from HTS. Drug Discov Today 1999; 4: 447–8

Loftus P. Quoted in: Brown P. Has R&D failed the pharmaceutical industry? Scrip Magazine 1994; July/August:3–4

Drews J , ed. In Quest of Tomorrow's Medicine (transl D Kramer). New York: Springer-Verlag, 1999

Butler D. IBM promises scientists 500-fold leap in supercomputing power… Nature 1999; 402: 705–6

Witt MR , Nielsen M. Characterisation of the influence of unsaturated free fatty acids on brain GABA/benzodiazepine receptor binding in vitro. J Neurochem 1994; 62: 1432–9

Horrobin DF. Development of agonist drugs. J Pharm Med 1991; 2: 69–80

Horrobin DF. The philosophical basis of drug target selection. Pharm Med 1996; 10: 29–42

Botez M , Young SN , Bachevalier J , Gauthier S. Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature 1979; 278: 182–3

Coppen A , Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised placebo-controlled trial. J Affect Disord (in press)

Freedman SD , Katz MH , Parker EM , Laposata M , Urman MY , Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(- / +) mice. Proc Natl Acad Sci USA 1999; 96: 3995–4000

Vaddadi K. Essential fatty acids and movement disorders. In: Peet M , Glen I , Horrobin DF , eds. Phospholipid Spectrum Disorder in Psychiatry. Carnforth: Marius Press, 1999: 285–95